1.No correlation between COMT genotype and entacapone benefi ts in Parkinson’s disease
Ji Seon Kim ; Ji-Young Kim ; Jong-Min Kim ; Jae Woo Kim ; Sun Ju Chung Sung ; R Kim RN ; Mi J. Kim ; Hee-Tae Kim ; Kyoung-Gyu Choi ; Dong-Ick Shin ; Young Hee Sung ; Kwang-Soo Lee ; Han-Joon Kim ; Jinwhan Cho ; Mee Young Park ; Hyun-Young Park ; SeongMin Choi ; Kun-Woo Park ; Ho-Won Lee ; Tae-Beom Ahn ; Oh Dae Kwon ; Sang-Jin Kim ; Beom S Jeon
Neurology Asia 2011;16(3):211-216
Catechol-O-methyltransferase (COMT) inhibitors are used to increase the bioavailability of therapeutic
L-dopa. We examined the effi cacy of entacapone in Parkinson’s disease patients who had daily “off”
duration of ≤2 hours, and carried different COMT polymorphisms. A total of 168 PD patients were
recruited from 19 centers. Subjects were administered with 100–200 mg of entacapone in combination
with each dose of L-dopa for 2 months. The clinical effi cacy was evaluated based on the activities
of daily living (ADL), score on the Unifi ed Parkinson’s Disease Rating Scale (UPDRS), Hoehn and
Yahr (H&Y) stage, and Clinical Global Impression (CGI). COMT polymorphisms were genotyped.
3-O-methyldopa (3-OMD) levels were measured before and after the administration of entacapone.
Entacapone administration produced signifi cant improvements in the total daily “on” duration, ADL,
UPDRS score, and H&Y stage. Nineteen patients (11.3%) had the low-activity COMT genotype,
68 patients (40.5%) had the intermediate-activity COMT genotype, and 81patients (48.2%) had the
high-activity COMT genotype. The effi cacy, and adverse effects of entacapone therapy did not differ
between the three groups. There was a signifi cant reduction in 3-OMD, but this did not differ among
the three genotypes. Entacapone provided an increased “on” duration and improved motor function
in all COMT genotypes.
Result Analysis
Print
Save
E-mail